Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel Heterozygous and Pathogenic Variant of the HNF1B Gene Associated with Autosomal Dominant Tubulointerstitial Kidney Disease with a Broad Spectrum of Extrarenal Phenotypes: A Case Report.
Kaimori JY, Matsuda J, Jan A, Kawano Y, Kawaoka T, Asahina Y, Doi Y, Oka T, Nagata M, Ishihara Y, Miyashita Y, Asano T, Sakaguchi Y, Isaka Y. Kaimori JY, et al. Among authors: kawaoka t. Intern Med. 2025 Jan 15. doi: 10.2169/internalmedicine.4548-24. Online ahead of print. Intern Med. 2025. PMID: 39814389 Free article.
Prognostic impact and risk factors of severe neutropenia in the early phase of treatment with trifluridine-tipiracil for metastatic colorectal cancer patients: a single-center retrospective study.
Omori Y, Matsukuma S, Kawa M, Ishimitsu K, Kawaoka T, Akiyama N, Tokuno K, Fujita Y, Sato S, Yamamoto S. Omori Y, et al. Among authors: kawaoka t. Int J Colorectal Dis. 2025 Jan 13;40(1):11. doi: 10.1007/s00384-024-04798-2. Int J Colorectal Dis. 2025. PMID: 39800823 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Kudo M, et al. Among authors: kawaoka t. Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798578 Clinical Trial.
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.
Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Nakahara H, et al. Among authors: kawaoka t. JCO Clin Cancer Inform. 2024 Dec;8:e2400108. doi: 10.1200/CCI.24.00108. Epub 2024 Dec 18. JCO Clin Cancer Inform. 2024. PMID: 39693579
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Miura R, et al. Among authors: kawaoka t. J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39652104
306 results